{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:01:58Z","timestamp":1746504118243,"version":"3.40.4"},"reference-count":39,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Grhta"],"abstract":"<jats:p>Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despiteits clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteractit. This study investigates the cost-effectiveness of Brentuximab Vedotin (BV) in combination with cyclophosphamide,doxorubicin and prednisone (CHP) for the front-line treatment of patients with sALCL in Italy.Methods: The analysis was conducted from the perspective of the National Health Service using a three-statepartitioned survival model with cycles lasting 21 days and a lifetime time horizon. The survival curves were takenfrom three-year follow-up data of ECHELON-2 trial. Costs were obtained from published literature and nationaltariffs. For all drugs, ex-factory prices net of the mandatory reductions required by law were considered.Results: Compared with CHOP, BV in combination with CHP was associated with an increase of \u20ac 46,349 totalcosts, 2.3 life years and 1.8 quality-adjusted life-years (QALYs) respectively. The incremental cost-utility ratios(ICUR) were estimated equal to \u20ac 25,367\/QALY compared with CHOP, resulting below the value of \u20ac 41,411\/QALYfor severe diseases in Italy.Conclusions: Based on data from 3 years of follow-up from the ECHELON-2 trial, BV in combination with CHP isestimated a cost-effective option versus CHOP for the front-line treatment of sALCL in Italy. Data from 5-year fromthe ECHELON-2 trial confirmed the advantage in terms of PFS and OS. The analysis also suggested that treatmentwith BV+CHP may be cost-effective compared with CHOEP.<\/jats:p>","DOI":"10.33393\/grhta.2025.3306","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:23:38Z","timestamp":1746429818000},"page":"106-117","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy"],"prefix":"10.33393","volume":"12","author":[{"given":"Andrea","family":"Marcellusi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-6542","authenticated-orcid":false,"given":"Chiara","family":"Bini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fioravanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Ripoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18642","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"16376","unstructured":"AIOM. Linee guida linfomi. Online https:\/\/www.aiom.it\/linee-guida-aiom-2018-linfomi\/ (Accessed September 2024)"},{"key":"16377","doi-asserted-by":"crossref","unstructured":"Quintanilla-Martinez L. The 2016 updated WHO classification of lymphoid neoplasias. Hematol Oncol. 2017;35(suppl 1):37-45. PMID:28591427","DOI":"10.1002\/hon.2399"},{"key":"16378","doi-asserted-by":"crossref","unstructured":"Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17-25. PMID:25869285","DOI":"10.1182\/blood-2014-10-567461"},{"key":"16379","doi-asserted-by":"crossref","unstructured":"Savage KJ, Harris NL, Vose JM, et al; International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496-5504. PMID:18385450","DOI":"10.1182\/blood-2008-01-134270"},{"key":"16380","doi-asserted-by":"crossref","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33(3):288-298. PMID:34921960","DOI":"10.1016\/j.annonc.2021.12.002"},{"key":"16381","unstructured":"EMA. RCP ADCETRIS. Online https:\/\/ec.europa.eu\/health\/documents\/community-register\/2019\/20190206143665\/anx_143665_en.pdf (Accessed September 2024)"},{"key":"16382","unstructured":"Gazzetta Ufficiale della Repubblica Italiana. Serie Generale n.223 del 17-09-2021. Online https:\/\/www.gazzettaufficiale.it\/atto\/serie_generale\/caricaDettaglioAtto\/originario?atto.dataPubblicazioneGazzetta=2021-09-17&atto.codiceRedazionale=21A05437&elenco30giorni=false. (Accessed September 2024)"},{"key":"16383","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229-240. PMID:30522922"},{"key":"16384","unstructured":"NCCN. T-Cell Lymphomas Guidelines. Version 4.2024. Online https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1483. (Accessed September 2024)"},{"key":"16385","doi-asserted-by":"crossref","unstructured":"Broccoli, A. and P.L. Zinzani, Peripheral T-cell lymphomas. Hematological Oncology. 2023;41(S1):7. DOI: 10.1002\/hon.3142","DOI":"10.1002\/hon.3142"},{"key":"16386","unstructured":"Supplemento ordinario n. 8 alla Gazzetta Ufficiale. Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero. Online http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=28\/01\/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001. (Accessed September 2024)"},{"key":"16387","doi-asserted-by":"crossref","unstructured":"Cranmer H, Trueman D, Evers E, Woodcock F, Podkonjak T. Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin. PharmacoEconom Open. 2022;6(6):881-892. PMID:36057890","DOI":"10.1007\/s41669-022-00349-z"},{"key":"16388","unstructured":"NICE. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma, TA478 Committee Papers. 2017; Online https:\/\/www.nice.org.uk\/guidance\/ta478. (Accessed September 2024)"},{"key":"16389","unstructured":"NICE. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma, TA524 Committee Papers. 2018; Online https:\/\/www.nice.org.uk\/guidance\/ta524\/documents\/html-content. (Accessed September 2024)"},{"key":"16390","unstructured":"NICE. Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma, TA577 Committee Papers. 2019; Online https:\/\/www.nice.org.uk\/guidance\/ta577. (Accessed September 2024)"},{"key":"16391","unstructured":"ISTAT. Tavole di mortalit\u00e0. Anno; 2022. Online https:\/\/demo.istat.it\/app\/?i=TVM (Accessed September 2024)"},{"key":"16392","doi-asserted-by":"crossref","unstructured":"Fautrel B, Boonen A, de Wit M, Grimm S, Joore M, Guillemin F. Cost assessment of health interventions and diseases. RMD Open. 2020;6(3):e001287. PMID:33148784","DOI":"10.1136\/rmdopen-2020-001287"},{"key":"16393","doi-asserted-by":"crossref","unstructured":"Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics-Ital Res Articles. 2009;11(1):83-93. DOI: 10.1007\/BF03320660","DOI":"10.1007\/BF03320660"},{"key":"16394","doi-asserted-by":"crossref","unstructured":"Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service. PharmacoEconomics. 2023;41(1):107-117. PMID:36434415","DOI":"10.1007\/s40273-022-01215-w"},{"key":"16395","doi-asserted-by":"crossref","unstructured":"Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990;10(3):212-214. PMID:2115096","DOI":"10.1177\/0272989X9001000308"},{"key":"16396","unstructured":"AIFA. Linee guida per la compilazione del dossier a supporto della domanda di rimborsabilit\u00e0 e prezzo di un medicinale ai sensi del D.M. 2 agosto 2019. Online https:\/\/www.aifa.gov.it\/documents\/20142\/1283800\/Linee_guida_dossier_domanda_rimborsabilita.pdf. (Accessed September 2024)"},{"key":"16397","doi-asserted-by":"crossref","unstructured":"Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-787. PMID:11747057","DOI":"10.1002\/hec.635"},{"key":"16398","doi-asserted-by":"crossref","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Press OU, ed. 2006. International Journal of Epidemiology, Volume 36, Issue 2, April 2007, Pages 476\u2013477, https:\/\/doi.org\/10.1093\/ije\/dym062","DOI":"10.1093\/ije\/dym062"},{"key":"16399","doi-asserted-by":"crossref","unstructured":"Cederleuf H, Bjerreg\u00e5rd Pedersen M, Jerkeman M, Relander T, d\u2019Amore F, Ellin F. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. Br J Haematol. 2017;178(5):739-746. PMID:28485010","DOI":"10.1111\/bjh.14740"},{"key":"16400","doi-asserted-by":"crossref","unstructured":"Sibon D, Nguyen DP, Schmitz N, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. 2019;104(12):e562-e565. PMID:31004022","DOI":"10.3324\/haematol.2018.213512"},{"key":"16401","unstructured":"Takeda. Data on file: Global ITC report for A+CHP vs CHOEP. 2019."},{"key":"16402","unstructured":"NICE DSU Technical Support Document 14: Survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. 2013. Online https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395885\/pdf\/Bookshelf_NBK395885.pdf. (Accessed September 2024)"},{"key":"16403","doi-asserted-by":"crossref","unstructured":"Wunderlich A, Kloess M, Reiser M, et al; German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin\u2019s lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin\u2019s Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14(6):881-893. PMID:12796026","DOI":"10.1093\/annonc\/mdg249"},{"key":"16404","unstructured":"Takeda, D.o.f., Brentuximab Vedotin for untreated Peripheral T-Cell Lymphoma (PTCL) UK Health Technology Assessment (HTA) and Strategy Advisory Board. Summary of the meeting."},{"key":"16405","unstructured":"Sostituire con: Decreto del Ministero della Salute 18 ottobre 2012. Tariffe delle prestazioni di assistenza specialistica ambulatoriale. Online: http:\/\/www.trovanorme.salute.gov.it\/norme\/renderPdf.spring?seriegu=SG&datagu=28\/01\/2013&redaz=13A00528&artp=3&art=1&subart=1&subart1=10&vers=1&prog=001. (Accessed September 2024)"},{"key":"16406","unstructured":"Ministero della Salute. Rapporto annuale sull\u2019attivit\u00e0 di ricovero ospedaliero. Dati SDO 2018. Online http:\/\/www.salute.gov.it\/imgs\/C_17_pubblicazioni_2898_allegato.pdf. (Accessed September 2024)"},{"key":"16407","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN guidelines for patients: Periprheral T-cell lymphoma. 2016. Online https:\/\/www.nccn.org\/patients\/guidelines\/nhl-peripheral\/files\/assets\/common\/downloads\/files\/peripheral.pdf. (Accessed September 2024)"},{"key":"16408","unstructured":"NHS; Lynphoma group. R-CHOP-21 \/ CHOP-21. Online https:\/\/nssg.oxford-haematology.org.uk\/lymphoma\/documents\/lymphoma-chemo-protocols\/L-80-r-chop-21.pdf. (Accessed September 2024)"},{"key":"16409","unstructured":"Nuffield Department of Population Health (NDPH). University of Oxford. Applied Methods of Cost-effectiveness Analysis in Healthcare. Online https:\/\/www.herc.ox.ac.uk\/downloads\/applied-methods-of-cost-effectiveness-analysis-in-healthcare. (Accessed September 2024)"},{"key":"16410","doi-asserted-by":"crossref","unstructured":"Zou D, Lee J, Kansal A, et al. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada. J Med Econ. 2022;25(1):324-333. PMID:35172685","DOI":"10.1080\/13696998.2022.2041320"},{"key":"16411","doi-asserted-by":"crossref","unstructured":"Chacker O, et al. The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France. 2022. 22 (1): S95. Online https:\/\/www.ispor.org\/docs\/default-source\/euro2021\/posteradcetriscemispor-euvf-pdf.pdf?sfvrsn=16121999_0. (Accessed September 2024)","DOI":"10.1016\/j.jval.2021.11.454"},{"key":"16412","doi-asserted-by":"crossref","unstructured":"McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics. 2008;26(9):733-744. PMID:18767894","DOI":"10.2165\/00019053-200826090-00004"},{"key":"16413","doi-asserted-by":"crossref","unstructured":"Feldman T, Zou D, Rebeira M, et al. Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL. Am J Manag Care. 2020;26(2):e41-e49. PMID:32059099","DOI":"10.37765\/ajmc.2020.42400"},{"key":"16414","doi-asserted-by":"crossref","unstructured":"W\u00f6hrer S, Chott A, Drach J, et al. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. Ann Oncol. 2004;15(11):1680-1683. PMID:15520071","DOI":"10.1093\/annonc\/mdh427"}],"container-title":["Global and Regional Health Technology Assessment"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3306\/3998","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3306\/3999","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/download\/3306\/3998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T07:23:46Z","timestamp":1746429826000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/grhta\/article\/view\/3306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,15]]}},"URL":"https:\/\/doi.org\/10.33393\/grhta.2025.3306","relation":{},"ISSN":["2283-5733","2284-2403"],"issn-type":[{"value":"2283-5733","type":"electronic"},{"value":"2284-2403","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}